Survey of a representative sample of patients after topical a) capsaicin 8% therapy b) lidocaine 5% therapy c) botulinum toxin A injection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011877

Enrollment

330

Registered

2017-05-04

Start date

2016-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with at least one of the capsaicin, lidocaine or botulinum toxin at least once

Interventions

Group 1: Patients who were treated with at least one of the capsaicin, lidocaine or botulinum toxin at least once from 2008-2017 are questioned once for profitability and abortion criteria

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who a) received at least one treatment with the topical capsaicin 8% (Qutenza ®) in the own clinic since 2010 b) since 2008 received at least one Versatis® therapy in the own clinic c) since 2014 received at least one Botox® injection in the own clinic

Exclusion criteria

Exclusion criteria: lack of ability to provide information, cognitive limitations

Design outcomes

Primary

Measure	Time frame
overview of the frequency / reasons for a possible discontinuation of therapy or the frequency / reasons for further treatment	—

Secondary

Measure	Time frame
Assessment of effectiveness (global impression)	—

Countries

Germany

Contacts

Public ContactMiriam Kaisler

Berufgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Abteilung für Schmerzmedizin

miriam.kaisler@bergmannsheil.de02343023248

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026